Literature DB >> 2829425

Expression of the v-rel oncogene in reticuloendotheliosis virus-transformed fibroblasts.

B E Moore1, H R Bose.   

Abstract

Reticuloendotheliosis virus (REV-T) induces a rapidly fatal lymphoma in chickens through the expression of its oncogene, v-rel, REV-T also morphologically transforms avian fibroblasts in vitro. These transformed cells displayed limited anchorage-independent growth and reached higher saturation density than uninfected or REV-A-infected fibroblasts. Morphologically transformed fibroblasts were tumorigenic when injected into the wing web of chickens. In transformed fibroblasts, the v-rel oncogene was expressed as a 57 kDa phosphoprotein with a half-life of 2 to 4 hr. A cellular phosphoprotein of about 40 kDa was also observed in immunoprecipitates of transformed fibroblasts. The subcellular location of the v-rel-encoded protein was determined using cell fractionation procedures and immunofluorescent staining. In acutely infected, nontransformed fibroblasts, pp57v-rel was associated with the nuclear region, but in morphologically transformed cells the v-rel protein was found in the cytoplasm. These observations suggest that the expression of the v-rel oncogene is insufficient for transformation and that the cellular localization of this transforming protein to the cytoplasm may be required for the progression to an altered cell phenotype in avian fibroblasts.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2829425     DOI: 10.1016/0042-6822(88)90478-3

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation.

Authors:  Andrew S Liss; Henry R Bose
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Avian reticuloendotheliosis virus-transformed lymphoid cells contain multiple pp59v-rel complexes.

Authors:  N Davis; W Bargmann; M Y Lim; H Bose
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

3.  AP-1 factors play an important role in transformation induced by the v-rel oncogene.

Authors:  J Kralova; A S Liss; W Bargmann; H R Bose
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

4.  The role of constitutive NF-kappaB activity in PC-3 human prostate cancer cell invasive behavior.

Authors:  P F Lindholm; J Bub; S Kaul; V B Shidham; A Kajdacsy-Balla
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  Avian I kappa B alpha is transcriptionally induced by c-Rel and v-Rel with different kinetics.

Authors:  J D Schatzle; J Kralova; H R Bose
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

6.  Transformation of avian fibroblasts overexpressing the c-rel proto-oncogene and a variant of c-rel lacking 40 C-terminal amino acids.

Authors:  J Kralova; J D Schatzle; W Bargmann; H R Bose
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

7.  The relocalization of v-Rel from the nucleus to the cytoplasm coincides with induction of expression of Ikba and nfkb1 and stabilization of I kappa B-alpha.

Authors:  R Hrdlicková; J Nehyba; A Roy; E H Humphries; H R Bose
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

8.  The v-rel oncogene product is complexed to a 40-kDa phosphoprotein in transformed lymphoid cells.

Authors:  H Y Tung; W J Bargmann; M Y Lim; H R Bose
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

9.  Mechanism of telomerase activation by v-Rel and its contribution to transformation.

Authors:  Radmila Hrdlicková; Jirí Nehyba; Andrew S Liss; Henry R Bose
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

10.  Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Zhen Fan; Douglas B Evans; Paul J Chiao
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.